Skip to main content

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project

Moreno, Lucas, Caron, Hubert, Geoerger, Birgit, Eggert, Angelika, Schleiermacher, Gudrun, Brock, Penelope, Valteau-Couanet, Dominique, Chesler, Louis, Schulte, Johannes H, De Preter, Katleen, and others. (2017) Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 12 (8). pp. 801-811. ISSN 1746-0441. E-ISSN 1746-045X. (doi:10.1080/17460441.2017.1340269) (KAR id:63861)

PDF Author's Accepted Manuscript
Language: English
Download (325kB) Preview
[img]
Preview
PDF (Abbreviations) Supplemental Material
Language: English
Download (185kB) Preview
[img]
Preview
PDF (Table 1) Supplemental Material
Language: English
Download (375kB) Preview
[img]
Preview
PDF (Table 2) Supplemental Material
Language: English
Download (243kB) Preview
[img]
Preview
PDF (Table 3) Supplemental Material
Language: English
Download (285kB) Preview
[img]
Preview
Official URL
http://dx.doi.org/10.1080/17460441.2017.1340269

Abstract

Introduction: Neuroblastoma, the commonest paediatric extra-cranial tumour, remains a leading cause of death from cancer in children. There is an urgent need to develop new drugs to improve cure rates and reduce long-term toxicity and to incorporate molecularly targeted therapies into treatment. Many potential drugs are becoming available, but have to be prioritised for clinical trials due to the relatively small numbers of patients.

Expert opinion: The Neuroblastoma NDDS is based on the premise that optimal drug development is reliant on knowledge of tumour biology and prioritisation. This approach will accelerate neuroblastoma drug development and other poor prognosis childhood malignancies.

Item Type: Article
DOI/Identification number: 10.1080/17460441.2017.1340269
Uncontrolled keywords: Neuroblastoma, drug development, phase I, preclinical testing, clinical trials
Subjects: Q Science
Divisions: Faculties > Sciences > School of Biosciences
Depositing User: Michelle Garrett
Date Deposited: 06 Oct 2017 08:31 UTC
Last Modified: 13 Mar 2020 04:09 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/63861 (The current URI for this page, for reference purposes)
Garrett, Michelle D.: https://orcid.org/0000-0002-3939-1673
  • Depositors only (login required):

Downloads

Downloads per month over past year